MMP9 and glioblastoma: Suppression of ANKRD37 and MMP9 expression may explain, at least in part, D11-mediated impaired migration of glioblastoma and pancreatic cancer cells reported previously [12] and indicates that treatment of glioblastoma cells with this compound compromises cell migration and invasion by suppressing the expression of proteins that are crucial in the metastatic process.